Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $49.55 USD
Change Today -0.53 / -1.06%
Volume 337.1K
IPXL On Other Exchanges
Symbol
Exchange
NASDAQ GS
As of 8:10 PM 04/24/15 All times are local (Market data is delayed by at least 15 minutes).

impax laboratories inc (IPXL) Key Developments

Impax Laboratories, Inc. Amends the Amended and Restated Bylaws

On and effective March 24, 2015, the Board of Directors of Impax Laboratories Inc., amended the amended and restated bylaws of the company. The amendment to the Bylaws amends Article II, Section 5 and Article II, Section 6 of the Bylaws to implement a majority vote standard for the election of directors in uncontested elections while retaining a plurality vote standard for contested elections.

Impax Laboratories Inc. Provides Earnings Guidance for 2015

Impax Laboratories Inc. provided earnings guidance for 2015. The company's full year 2015 estimates, which include the newly acquired companies, are based on management's current belief about prescription trends, pricing levels, inventory levels, and the anticipated timing of future product launches and events. The company's estimates exclude the impact from any products for which the company has not yet received approval from the U.S. Food and Drug Administration. Adjusted gross margins as a percent of total revenue are expected to be in the mid 50% range, excluding preliminary projections of Hayward facility remediation costs. capital expenditures of approximately $45 million to $50 million; effective tax rate of approximately 34% to 36% on a GAAP basis, which assumes that the U.S. R&D tax credit is renewed for 2015. The company anticipates that its non-GAAP effective tax rate may experience volatility as the company's tax benefits may be high compared to the company's operating income or loss. The company anticipates that its non-GAAP effective tax rate may experience volatility as the company's tax benefits may be high compared to the Company's operating income or loss.

Impax Laboratories Inc., 2015 Guidance/Update Call, Mar 10, 2015

Impax Laboratories Inc., 2015 Guidance/Update Call, Mar 10, 2015

Impax Eyes Acquisitions

Impax Laboratories Inc. (NasdaqGS:IPXL) is looking for acquisition opportunities. Mark Donohue, Vice President of Investor Relations and Corporate Communications of Impax, said, we began the process of diversifying our portfolio by using both external partnerships and through acquisitions.

Impax Laboratories Inc. Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014

Impax Laboratories Inc. reported unaudited consolidated earnings results for the fourth quarter and full year ended December 31, 2014. For the quarter, the company reported total revenues of $131,211,000 compared to $100,741,000 for the same period a year ago. Profit from operations was $1,154,000 compared to loss of $16,234,000 for the same period a year ago. Income before income taxes was $1,650,000 compared to loss before income taxes of $15,835,000 for the same period a year ago. Net income was $120,000 or nil per diluted share compared to net loss of $9,622,000 or $0.14 diluted loss per share for the same period a year ago. Adjusted net income was $11,033,000 or $0.16 per diluted share compared to adjusted net loss of $1,641,000 or $0.02 per diluted share for the same period a year ago. Adjusted EBITDA was $27,431,000 compared to $1,639,000 for the same period a year ago. EBITDA was $7,225,000 compared to negative EBITDA of $12,605,000 for the same period a year ago. For the year, the company reported total revenues of $596,049,000 compared to $511,502,000 for the same period a year ago. Profit from operations was $88,816,000 compared to loss of $6,387,000 for the same period a year ago. Income before income taxes was $90,559,000 compared to income of $146,940,000 for the same period a year ago. Net income was $57,353,000 or $0.81 per diluted share compared to net income of $101,259,000 or $1.47 per diluted share for the same period a year ago. Net cash provided by operating activities was $32,817,000 compared to $149,940,000 for the same period a year ago. Purchases of property, plant and equipment were of $29,913,000 compared to $32,785,000 for the same period a year ago. Adjusted net income was $93,205,000 or $1.32 per diluted share compared to adjusted net income of $56,112,000 or $0.82 per diluted share for the same period a year ago. EBITDA was $112,073,000 compared to $165,692,000 for the same period a year ago. Adjusted EBITDA was $186,671,000 compared to $115,420,000 for the same period a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
IPXL:US $49.55 USD -0.53

IPXL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for IPXL.
View Industry Companies
 

Industry Analysis

IPXL

Industry Average

Valuation IPXL Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact IMPAX LABORATORIES INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.